After Hour Gainers / Losers

Top gainers, as of 5:15 p.m.: JCP +13.3%. BEAT +12.7%. SB +8.1%. BIDU +6.5%. SZYM +5.8%.

Top losers, as of 5:15 p.m.: NKTR -10.4%. HK -8.3%. NDLS -6.7%. STAA -6.6%. INO -6.4%.

From other sites
Comments (6)
  • makadik
    , contributor
    Comments (2) | Send Message
    any news detail from public offering.
    26 Feb 2014, 06:33 PM Reply Like
  • wmcraigbarnard
    , contributor
    Comments (206) | Send Message
    It's appropriate to note this offering is underwritten. This means it has a guarantee that all shares will either be sold or the Underwriter will buy them. No underwriter will risk their credit or company by underwriting a bad company.


    This means the companies stock will have quality market makers >>brokers<< bringing in investors. When an offering like this is made they offer it to their deepest pockets first. This means >>investor class<< not traders. The traders will also be there but this offering isn't so big. I keep in mind the coming news, which is expected to be positive, will drive prices to appropriate levels, even with this increase in the float. These things don't generally happen very quickly. They can, but generally the market has to be stable enough to handle it.


    Another thing no one seems to be thinking about. At what strike price will the offer be sold. If it is at or about $4.50 that is good for the market. There is a reason the company has initiated market support. The offering could be offered at $3.75. This higher the better as it puts a new floor in the stock price. Also if they come in high enough it may drive the shorts into buying to cover.


    Honestly I am hoping the company comes out around $5.00. But honestly that is my hope as things sit today. If the stock stabilizes higher and the chickens get out this could be very rewarding.


    The real price the stock should be in my opinion based on caparisons of others is a little over $10.00 to $12.00. AND this is before they have their Phase 2 report.


    Inovio Pharmaceuticals Announces Public Offering of Common Stock 24 minutes ago - PR Newswire via Dow Jones News


    BLUE BELL, Pa., Feb. 26, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) ("Inovio" or the "Company"), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint bookrunning managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
    26 Feb 2014, 07:40 PM Reply Like
  • VisionMoney
    , contributor
    Comments (65) | Send Message
    There was a “heads-up” article about this S-3 filling, by BRG(2/2/14).
    It’s a must read for $INO investors.


    Also BRG asked CEO of Inovio about this S-3 filling in another interview.


    Strategically, shelves(S-3) can be utilized at opportunities when share prices are high.


    My guess is that, INO can utilize the shelves after Phase 2 result and/or after reaching its scheduled milestones in 2014 & after the eventual share price increases. (INO has 3 years to utilize it.)


    Shelving near $10-$20 per share range can lead to very small dilution for raising whopping $125 million reserve money. ($5 range can be acceptable as well.)


    That’d be a brilliant move :-)
    27 Feb 2014, 06:33 AM Reply Like
  • VisionMoney
    , contributor
    Comments (65) | Send Message
    With $55million raised this time, INO has about $100 million reserve money. This puts them in quite solid cash position & shows INO is a serious biotech company.


    INO isn’t necessarily utilizing “all” of its shelvings right now.
    INO can offer shelvings incrementally as the share price increases over time.


    Next one maybe after the positive phase 2 read-out in mid-2014. Hopefully, near $10.
    27 Feb 2014, 03:26 PM Reply Like
  • longimgn
    , contributor
    Comments (934) | Send Message
    As far as offering price, I am no analyst or anything, but I always thought it was based on the average trading pps for the last 2 weeks or something like that....I don't think they can offer it for more than what it is currently selling at......but if I am incorrect, please correct me as I have sooooo much to learn.....cheers, long
    26 Feb 2014, 08:20 PM Reply Like
  • wmcraigbarnard
    , contributor
    Comments (206) | Send Message
    Looks like my pricing thoughts were very wrong. I was really hoping the company would raise the floor a little higher. The stock is undervalued when one considers that the future profit potential is so very significant.


    These type stocks as well as tech stocks have a special pricing consideration. Since they do have significant development lead times, and so long as they have favorable reports concerning product development, prices are not held to the same formula stocks/companies are usually held tool Example ALNY and TSLA. Neither seem to deserve their price structure yet analysts seem to be comfortable with the promise of forward looking profit.


    It is stunning I know. It's not my opinion this vry topic has been discussed in articles and on TV among those who promoted tech and pharma. This is what drove my thinking about the possibility of a little higher priced offering. Either way i invest in companies not stock price. That follows so long as the company is sound.


    Be well all.
    27 Feb 2014, 09:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs